Contributions
Abstract: EP1357
Type: ePoster
Abstract Category: Clinical aspects of MS - 6 MS and gender
Background: Multiple Sclerosis (MS) is commonly diagnosed in women of childbearing age and pregnancy management and outcomes are highly relevant to this patient population. PREG-MS, the first prospective regional MS pregnancy registry in the United States, follows women with MS and their children from pre-conception and any stage of conception to three years postpartum.
Methods: Detailed information on fertility, Assisted Reproductive Technologies (ART) disease modifying therapy (DMT) exposure, disease course, pregnancy course, and pediatric developmental outcomes is being collected through structured telephone interviews every 3 months, and medical records review.
Results: To date, study enrolled 50 women. 34% are in pregnancy planning stages, and 66% have either completed pregnancy or are currently pregnant with average time to conception of 3.4 (0.5-24) months. 30% of all subjects used ART. 10% of this group have failed one or more IVF cycles and all had moderate relapse within 6-months post treatment. Spontaneous 1st trimester pregnancy loss was 9%. 31% of pregnancies were exposed to DMTs including 2 patients who received glatiramer acetate (GA) throughout pregnancy. A third of patients reported pregnancy complications, regardless of DMT exposure, including preeclampsia, preterm labor, hypertension, low amniotic fluid, preterm amniotic sac rupture and excessive hemorrhage during labor. Preeclampsia and placental abruption were seen in mothers, and low birth weight and increased muscle tone at birth was seen in infant,with full-term GA exposure. Persistent motor developmental delay and ventricular septal defect were seen in infant of mother exposed to fingolimod. Infants born to non-DMT exposed mothers had low birth weights (22%) and reversible developmental delays (24%).
Conclusion: Data from this pregnancy registry contributes to our understanding of disease activity and DMT exposure effects on fertility, maternal and pediatric developmental outcomes. Prospective real world pregnancy registries can provide foundation for comprehensive disease management programs during pregnancy and postpartum.
Disclosure:
Maria Houtchens: Unrestricted research grants from Biogen Idec, GenzymeConsulting honorarium from Teva Neurosciences, Biogen Idec, Novartis, Genzyme.
No conflicts with this abstract
Tatenda D Mahlanza: nothing to disclose
Abstract: EP1357
Type: ePoster
Abstract Category: Clinical aspects of MS - 6 MS and gender
Background: Multiple Sclerosis (MS) is commonly diagnosed in women of childbearing age and pregnancy management and outcomes are highly relevant to this patient population. PREG-MS, the first prospective regional MS pregnancy registry in the United States, follows women with MS and their children from pre-conception and any stage of conception to three years postpartum.
Methods: Detailed information on fertility, Assisted Reproductive Technologies (ART) disease modifying therapy (DMT) exposure, disease course, pregnancy course, and pediatric developmental outcomes is being collected through structured telephone interviews every 3 months, and medical records review.
Results: To date, study enrolled 50 women. 34% are in pregnancy planning stages, and 66% have either completed pregnancy or are currently pregnant with average time to conception of 3.4 (0.5-24) months. 30% of all subjects used ART. 10% of this group have failed one or more IVF cycles and all had moderate relapse within 6-months post treatment. Spontaneous 1st trimester pregnancy loss was 9%. 31% of pregnancies were exposed to DMTs including 2 patients who received glatiramer acetate (GA) throughout pregnancy. A third of patients reported pregnancy complications, regardless of DMT exposure, including preeclampsia, preterm labor, hypertension, low amniotic fluid, preterm amniotic sac rupture and excessive hemorrhage during labor. Preeclampsia and placental abruption were seen in mothers, and low birth weight and increased muscle tone at birth was seen in infant,with full-term GA exposure. Persistent motor developmental delay and ventricular septal defect were seen in infant of mother exposed to fingolimod. Infants born to non-DMT exposed mothers had low birth weights (22%) and reversible developmental delays (24%).
Conclusion: Data from this pregnancy registry contributes to our understanding of disease activity and DMT exposure effects on fertility, maternal and pediatric developmental outcomes. Prospective real world pregnancy registries can provide foundation for comprehensive disease management programs during pregnancy and postpartum.
Disclosure:
Maria Houtchens: Unrestricted research grants from Biogen Idec, GenzymeConsulting honorarium from Teva Neurosciences, Biogen Idec, Novartis, Genzyme.
No conflicts with this abstract
Tatenda D Mahlanza: nothing to disclose